Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: In vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy

Journal of Drug Targeting

Volumn 23, Issue 5, 2015, Pages 436-443

  Gao, Meng ^a   Yao, Nan ^a   Huang, Dejian ^a   Jiang, Cuihua ^a   Feng, Yuanbo ^a,b   Li, Yue ^a   Lou, Bin ^a   Peng, Fei ^a   Sun, Ziping ^c   Ni, Yicheng ^a,b   Zhang, Jian ^a  

^a Jiangsu Provincial Hospital of Chinese Medicine   (China)

^b DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Combretastatin A 4 phosphate (CA4P); Inductively coupled plasma atomic emission spectroscopy (ICP AES); Magnetic resonance imaging (MRI); Trapping effect; Tumor

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; GADOLINIUM PENTETATE MEGLUMINE; PHOSPHATE BUFFERED SALINE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; GADOLINIUM PENTETATE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; AUTOPSY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMORTEM INDUCTIVELY COUPLED PLASMA ATOMIC EMISSION SPECTROSCOPY; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO; ANIMAL; ATOMIC ABSORPTION SPECTROMETRY; CARCINOMA, HEPATOCELLULAR; DISEASE MODEL; LIVER NEOPLASMS; MOUSE; PATHOLOGY; PROCEDURES; TIME; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; SPECTROPHOTOMETRY, ATOMIC; STILBENES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84930629334     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.1002789     Document Type: Article

References (28)

1. Carr C, Ng J, Wigmore T. The side effects of chemotherapeutic agents. Curr Anaesth Crit Care 2008;19:70-9.
2. Allen TM, Charrois GJR, Sapra P. Recent advances in passively and actively targeted liposomal drug delivery systems for the treatment of cancer. Abstracts of Papers of the American Chemical Society. 2003;226:U458-U.
3. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
4. Banciu M, Metselaar JM, Schiffelers RM, Storm G. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J Steroid Biochem Mol Biol 2008; 111:101-10.
5. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
6. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Invest Drugs (Lond, England: 2000) 2006;7:522-8.
7. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60:155-61.
8. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2000;21:93-102.
9. Tozer G, Kanthou C, Lewis G, et al. Tumour vascular disrupting agents: combating treatment resistance. Brit J Radiol 2008;81: 12-20.
10. Grosios K, Loadman PM, Swaine DJ, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20:229-33.
11. Rustin GJ, Shreeves G, Nathan PD, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102:1355-60.
12. Zweifel M, Jayson G, Reed N, et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinumresistant ovarian cancer: final phase II trial results. J Clin Oncol 2009;27:15S. Abstr no: 5502.
13. Wildiers H, Ahmed B, Guetens G, et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer. 2004;40:284-90.
14. Wang HJ, Sun XH, Chen F, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009;44:44-53.
15. Wang H, Sun X, Chen F, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009;44: 44-53.
16. Feng Y, Xie Y, Wang H, et al. A modified rabbit model of reperfused myocardial infarction for cardiac MR imaging research. Int J Cardiovasc Imaging 2009;25:289-98.
17. Li X, Coles BJ, Ramsey MH, Thornton I. Sequential extraction of soils for multielement analysis by ICP-AES. Chem Geol 1995;124: 109-23.
18. Zhao F, McGrath S, Crosland A. Comparison of three wet digestion methods for the determination of plant sulphur by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Commun Soil Sci Plant Anal 1994;25:407-18.
19. Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Therapy Rev 2005;1:1-9.
20. Tozer G, Kanthou C.Tumor vascular disrupting agents. In: Domenico Ribotti, ed. Recent advances in angiogenesis and antiangiogenesis. Sharjah: Bentham Science Publishers; 2009:101-11.
21. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457-64.
22. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Cancer Nanotechnology, Methods Mol Biol 2010;624:25-37.
23. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812-18.
24. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2:751-60.
25. Popovic Z, Liu WH, Chauhan VP, et al. A nanoparticle size series for in vivo fluorescence imaging. Angew Chem, Int Ed 2010;49: 8649-52.
26. Weinmann H-J, Brasch RC, Press W-R, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 1984;142:619-24.
27. Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987;36:1925-32.
28. Dreher MR, Liu WG, Michelich CR, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335-44.